JOSEPH A. KOVACS, M.D.; ANDREA A. KOVACS, M.D.; MICHAEL POLIS, M.D.; W. CRAIG WRIGHT, M.D.; VEE J. GILL, Ph.D.; CARMELITA U. TUAZON, M.D.; EDWARD P. GELMANN, M.D.; H. CLIFFORD LANE, M.D.; ROBERT LONGFIELD, M.D.; GARY OVERTURF, M.D.; ABE M. MACHER, M.D.; ANTHONY S. FAUCI, M.D.; JOSEPH E. PARRILLO, M.D.; JOHN E. BENNETT, M.D.; HENRY MASUR, M.D.
The clinical course and response to therapy of 27 patients with cryptococcosis and the acquired immunodeficiency syndrome were reviewed. Cryptococcosis was the initial manifestation of the syndrome in 7 patients, and the initial opportunistic infection in an additional 7. Meningitis was the commonest clinical feature (18 patients). Blood cultures and serum cryptococcal antigen were frequently positive. In patients with meningitis, leukocyte count, protein level, and glucose level in cerebrospinal fluid were frequently normal; cerebrospinal fluid India ink test (82%), culture (100%), and cryptococcal antigen (100%) were usually positive. Only 10 of 24 patients had no evidence of clinical activity of cryptococcal infection after completion of therapy; 6 of these 10 had relapses shown by clinical findings or at autopsy. Standard courses of amphotericin B alone or combined with flucytosine were ineffective. Cryptococcosis in patients with the syndrome is a debilitating disease that does not respond to conventional therapy; earlier diagnosis or long-term suppressive therapy may improve the prognosis.
KOVACS JA, KOVACS AA, POLIS M, WRIGHT WC, GILL VJ, TUAZON CU, et al. Cryptococcosis in the Acquired Immunodeficiency Syndrome. Ann Intern Med. ;103:533–538. doi: 10.7326/0003-4819-103-4-533
Download citation file:
Published: Ann Intern Med. 1985;103(4):533-538.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use